Jae Lee
Adult Health · Baltimore, MDNPI 1073776985
Payments from drug & device makers
Across 96 payments — averaging $34.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$835
- Madrigal Pharmaceuticals$371
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$330
- Takeda Pharmaceuticals U.S.A., Inc.$248
- Mallinckrodt Hospital Products Inc.$232
- Daiichi Sankyo Inc.$147
- plus $1K from 23 others
What the payments were for
- Consulting fees$70021%
- Food & beverage$2,60679%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 7 | $835 |
| Madrigal Pharmaceuticals | 9 | $371 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $330 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $248 |
| Mallinckrodt Hospital Products Inc. | 8 | $232 |
| Daiichi Sankyo Inc. | 6 | $147 |
| AbbVie | 6 | $128 |
| Johnson & Johnson | 4 | $126 |
| Ipsen Biopharmaceuticals, Inc | 5 | $118 |
| Karyopharm Therapeutics Inc. | 1 | $118 |
| Secura Bio, Inc. | 1 | $106 |
| Intercept Pharmaceuticals, Inc. | 4 | $97 |
| Shield Therapeutics Inc | 3 | $67 |
| QOL Medical, LLC | 1 | $37 |
| Aimmune Therapeutics, Inc. | 1 | $35 |
| Novo Nordisk | 2 | $35 |
| Sandoz | 1 | $30 |
| Ardelyx, Inc. | 1 | $25 |
| Genentech USA, Inc. | 1 | $25 |
| Exact Sciences | 1 | $23 |
| Ironwood Pharmaceuticals, Inc | 1 | $23 |
| Pfizer | 1 | $22 |
| Organon | 2 | $22 |
| Pharmacosmos Therapeutics Inc. | 1 | $22 |
| Merck | 1 | $19 |
| W. L. Gore & Associates, Inc. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Orphalan Inc | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,306 in reported general payments places this provider in the 85th percentile of 542 adult health providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OcalivaObeticholic Acid | 12 | $112,074 |
| VemlidyTenofovir Alafenamide | 53 | $80,888 |
| Envarsus XrTacrolimus | 16 | $33,757 |
| Tacrolimus | 93 | $22,643 |
| Entecavir | 40 | $22,638 |
| Ursodiol | 80 | $18,136 |
| Sirolimus | 42 | $13,276 |
| Tenofovir Disoproxil Fumarate | 24 | $5,201 |
| Mycophenolate Mofetil | 39 | $2,752 |
| Nadolol | 14 | $1,777 |
| Azathioprine | 29 | $1,342 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 62 | $1,137 |
| Spironolactone | 11 | $267 |
| Carvedilol | 23 | $221 |
| Pantoprazole Sodium | 18 | $150 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Intercept Pharmaceuticals, Inc.Ocaliva | $97 | $112,07412 claims |
| GileadVemlidy | $835 | $80,88853 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 542 adult health providers in Maryland.
Other adult health in Baltimore
- Christopher RobersonBaltimore$180K
- Amit DhirBaltimore$97K
- Angie PriceBaltimore$96K
- Brendon BowerBaltimore$64K
- Caitlin NassBaltimore$46K
- Sarah RileyBaltimore$24K
- Monica LovinsBaltimore$18K
- Elizabeth ChandlerBaltimore$17K
- Clifton DawsonBaltimore$14K
- Selina YeasminBaltimore$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.